ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2743

CD27 Is a Key Regulator of T Cell Responses

Michael Scully1, Nicole Wunderler2, Holger Babbe1, Yevgeniya Orlovsky2, Galina Obmolova3, Ann Cai1, Heath Guay4, Jacqueline Benson4 and Tatiana Ort1, 1Research Immunology, Immunology Research, Janssen Research and Development, LLC, Spring House, PA, 2Immunology Research, Janssen Research and Development, LLC, Spring House, PA, 3Biologics Research, Janssen Research and Development, LLC, Spring House, PA, 4Estrela Lupus Venture, Janssen Research and Development, LLC., Spring House, PA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Immune regulation, T cells and co-stimulation

  • Tweet
  • Email
  • Print
Session Information

Title: T cell Biology in Lupus, Vasculitis, Myositis and Other Autoimmunity

Session Type: Abstract Submissions (ACR)

Background/Purpose: CD27 is a member of the TNF superfamily of receptors that is expressed on a majority of natural killer (NK) cells, T cells, memory B cells and antibody-secreting plasma cells in humans.  CD70 is the only known ligand for CD27 and is transiently expressed on activated dendritic cells, B cells and T cells.  Much of our understanding of the immunological role of CD27 comes from studies with mouse models, which suggest that CD27 is a key regulator of NK cell, T cell and B cell responses. Here, we used an in-house generated neutralizing, antagonistic antibody to evaluate the role of CD27 in regulating human and primate immune responses using in vitro and in vivo models.

Methods: To examine the role of CD27 in immune cell biology, we generated a neutralizing, antagonistic and non-depleting human anti-human CD27 antibody.  To assess the contribution of CD27 signaling to human immune responses in vitro, we examined the effects of CD27 blockade on Ig-production by B cells, proliferation of naive CD4+ T cells and cytokine production by healthy volunteer PBMCs in vitro.  To understand the role of CD27 on immune responses in vivo, we examined the effects of CD27 blockade on T and B cell responses in a cynomolgus monkey Delayed Type Hypersensitivity (DTH) model.  To further explore the contribution of CD27 to human T cell responses in vivo, we examined the effects of CD27 blockade on human T cell engraftment in the NSG (NOD/SCID IL-2Rγ-/-) human CD45+ peripheral blood cell → mouse GVH model.  

Results: We found that neutralizing the CD27 pathway inhibited CD70-induced Ig-secretion by activated human B cells, whereas blockade of CD27 in an autologous T cell:B cell co-culture model did not impact Ig-secretion in vitro (despite expression of CD70 on cells in this system).  Treatment with an anti-CD27 antibody dose-dependently attenuated CD70-mediated induced proliferation of primary human CD4+ T cells and decreased the production of pro-inflammatory cytokines by healthy control PBMCs in vitro.  Treatment with an anti-CD27 antibody reduced human CD45+ CD4+ and CD8+ cell numbers in the spleen and peripheral blood of host mice in the human cell → NSG mouse GVH model.  Blockade of CD27 reduced T cell infiltration into the challenge site in response to a neo-antigen, but did not impact antigen-specific antibody titers in a cynomolgus monkey DTH model.

Conclusion: These data demonstrate that CD27 can promote Ig-production by human B cells, but may play a redundant role in some types of B cell responses.  In contrast, CD27 appears to play a critical role in the generation of both CD4+ and CD8+ T cell responses.  These data suggest that the CD27 pathway modulates the activity of multiple human immune cell types, and that blockade of the CD27 pathway may present a novel therapeutic strategy for the treatment of immune mediated diseases.


Disclosure:

M. Scully,

Janssen Research and Development,

3;

N. Wunderler,

Janssen Research and Development,

3;

H. Babbe,

Janssen Research and Development,

3;

Y. Orlovsky,

Janssen Research and Development,

3;

G. Obmolova,

Janssen Research and Development,

3;

A. Cai,

Janssen Research and Development,

3;

H. Guay,

Janssen Research and Development,

3;

J. Benson,

Janssen Research and Development, LLC.,

3;

T. Ort,

Janssen Research and Development,

3.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cd27-is-a-key-regulator-of-t-cell-responses/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology